Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure

NCT ID: NCT06578520

Last Updated: 2025-08-06

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-07-30
• Study Completion Date: 2025-12-31

Brief Summary

Cross-over, 2-sequence, 2-treatment, 2-period single-centre, phase IV, randomized, open label study.

Detailed Description

Peritoneal dialysis (PD) is a technique that has been successfully used for the treatment of refractory heart failure to diuretics. In patients on PD, the harmful effects of sodium retention become even greater, resulting in fluid overload, hypertension and left ventricular hypertrophy in more than half of the PD population. This is due to the fact that the accumulation of sodium in the skin interstitium would generate an inflammatory environment and, therefore, the activation of growth and fibrogenic factors with a consequent increase in cardiac muscle mass.

In patients with HF receiving PD, therefore, it is necessary to reduce salt intake with diet, as well as to ensure adequate elimination through available medical treatments and elimination of Na through the most appropriate dialysis technique.

In recent years, a new player has joined the treatment of HF: iSGLT2, an oral hypoglycaemic drug. ISGLT2 promotes natriuresis thanks to its well-known mechanism of inhibition of Na and glucose co-transporter. Also promoting excretion of Na at the distal tubule level due to increased tubular osmotic pressure secondary to glycosuria, as well as by direct inhibition of NH3 channels reabsorbing Na and Hydrogens.

The purpose of the study is to analyse whether the use of an SGLT2 inhibitor (Dapagliflozin) in patients with CKD and HF treated with peritoneal dialysis can benefit patients in terms of increased total elimination of sodium and water.

In this study, dapagliflozin will be used together with established drug therapy for patients with HF, including concomitant diuretic therapy.

after randomization, the patient will be divided in two groups and they will receive the study drug or placebo for 8 weeks and, after a 4-week wash out, each patient will switch groups for further 8 weeks to receive standard of care or standard of care plus Dapaglifozin as appropriate.

The study will end with a safety extension study in which all patients will take Dapagliflozin for a further 8 weeks.

Conditions

Heart Failure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group 1

They will receive standard of care plus Dapaglifozin for 8 weeks, after a 4-week wash out, they will receive receive standard of care for another 8 weeks.

Group Type: EXPERIMENTAL

Dapagliflozin

Intervention Type: DRUG

10 mg once per day, oral tablets

Group 2

They will receive standard of care for 8 weeks, after a 4-week wash out, they will receive receive standard of care for another 8 weeks plus Dapaglifozin.

Group Type: EXPERIMENTAL

Dapagliflozin

Intervention Type: DRUG

10 mg once per day, oral tablets

Interventions

Dapagliflozin

10 mg once per day, oral tablets

Intervention Type: DRUG

Other Intervention Names

Forxiga

Eligibility Criteria

Inclusion Criteria

• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• Provision of informed consent form prior to any study specific procedures, sampling and analysis.
• Individuals must be ≥ 18 years of age at the time of signing the informed consent
• Individuals must have a confirmed diagnosis of Heart Failure (HF) according to clinical practice guidelines NYHA functional class I-III (with HFrEF or HFpEF).
• In treatment with Peritoneal Dialysis technique
• Chronic Kidney Disease (eGFR < 60 ml/min/m2 CKD-EPI formula)
• PD vintage of more than 30 days
• On stable doses of furosemide, or alternative loop diuretic for 14 days
• On stable HF therapy for at least 1 month prior to consent
• No hospitalizations for HF for at least 1 month prior to consent

Exclusion Criteria

• Limited life expectancy (less than 1 year) based on investigator's clinical judgement.
• Patients without indication of beginning treatment with Dapagliflozin according to the Data Sheets and Consumer Medicine Information.
• Malignancy (with active treatment) or other life-threatening disease
• Patients in whom proper study compliance cannot be guaranteed
• Rejection or revocation of informed consent
• Current acute decompensated HF, hospitalization due to decompensated HF, myocardial infarction, unstable angina, stroke or transient ischemic attack within 1 month prior to enrollment.
• Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting or valvular repair/replacement) within 1 month prior to enrollment or planned to undergo any of these operations after randomization.
• Implantation of a Cardiac Resynchronization Therapy (CRT) device or Implantable Cardioverter Defibrillator (ICD) within 1 month prior to enrollment or intent to perform atrial fibrillation ablation or to implant a CRT or ICD device.
• Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or transplantation or implantation expected after randomization
• Pregnant or breast-feeding women
• Type 1 Diabetes
• Residual urine volume less than 500ml daily or reduction in urinary output by 24 hours (< 30% compared to previous routine control) within 30 days prior to consent
• Patients with amputated limbs will be excluded of bioimpedance analysis.
• Participation in another clinical study with an investigational product during the last 3 months.
• Patients with a known hypersensitivity to Dapagliflozin or any of the excipients of the product.
• Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site).
• Judgment by the investigator that the subject should not participate in the study if the subject is unlikely to comply with study procedures, restrictions and requirements.
• Previous enrolment in the present study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fundación para la Investigación del Hospital Clínico de Valencia

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Marco Montomoli

Role: PRINCIPAL_INVESTIGATOR

Hospital Clínico Universitario de Valencia

Locations

Hospital Clínico Universitario de Valencia

Valencia, , Spain

Site Status: RECRUITING

Countries

Spain

Central Contacts

Marco Montomoli

Role: CONTACT

marcomontomoli@hotmail.it

961 973500 ext. 436361

Facility Contacts

Marco Montomoli

Role: primary

marcomontomoli@hotmail.it

Other Identifiers

DAPA-DP

Identifier Type: -

Identifier Source: org_study_id